# L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL

> **NCT01910428** · PHASE1 · TERMINATED · sponsor: **ERYtech Pharma** · enrollment: 14 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma

## Interventions

- **DRUG:** L-asparaginase encapsulated in RBC

## Key facts

- **NCT ID:** NCT01910428
- **Lead sponsor:** ERYtech Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2018-01-25
- **Final completion:** 2018-03
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Sponsor decision based off site/PI feedback about
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910428, "L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01910428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*